ATE235248T1 - Verfahren zur identifizierung und isolierung von einem molekül - Google Patents

Verfahren zur identifizierung und isolierung von einem molekül

Info

Publication number
ATE235248T1
ATE235248T1 AT00117699T AT00117699T ATE235248T1 AT E235248 T1 ATE235248 T1 AT E235248T1 AT 00117699 T AT00117699 T AT 00117699T AT 00117699 T AT00117699 T AT 00117699T AT E235248 T1 ATE235248 T1 AT E235248T1
Authority
AT
Austria
Prior art keywords
host cells
molecule
lysates
sample
binding partners
Prior art date
Application number
AT00117699T
Other languages
English (en)
Inventor
Michael Pfreundschuh
Hans-Georg Rammensee
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/580,980 external-priority patent/US6025191A/en
Priority claimed from US08/644,116 external-priority patent/US6140464A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE235248T1 publication Critical patent/ATE235248T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811Selection methods for production or design of target specific oligonucleotides or binding molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
AT00117699T 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül ATE235248T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/479,328 US5698396A (en) 1995-06-07 1995-06-07 Method for identifying auto-immunoreactive substances from a subject
US08/580,980 US6025191A (en) 1995-06-07 1996-01-03 Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US08/644,116 US6140464A (en) 1995-06-07 1996-05-10 Nonapeptides that bind a HLA-A2.1 molecule

Publications (1)

Publication Number Publication Date
ATE235248T1 true ATE235248T1 (de) 2003-04-15

Family

ID=23903564

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96919266T ATE222116T1 (de) 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül und von diesem erkannte moleküle
AT00117699T ATE235248T1 (de) 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96919266T ATE222116T1 (de) 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül und von diesem erkannte moleküle

Country Status (11)

Country Link
US (2) US5698396A (de)
EP (1) EP0831879B1 (de)
JP (1) JP2002502354A (de)
CN (1) CN1136914C (de)
AT (2) ATE222116T1 (de)
CA (1) CA2223566C (de)
DE (2) DE69623014T2 (de)
DK (1) DK0831879T3 (de)
ES (1) ES2180782T3 (de)
PT (1) PT831879E (de)
WO (1) WO1996040209A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
ES2200150T3 (es) 1996-01-23 2004-03-01 The Board Of Trustees Of The Leland Stanford Junior University Procedimiento de cribaje de peptidos efectores transdominantes y moleculas de arn.
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6027916A (en) 1996-10-09 2000-02-22 Human Genome Sciences, Inc. Galectin 9 and 10SV Polynucleotides
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6403373B1 (en) 1997-10-10 2002-06-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these
US6218521B1 (en) 1997-07-17 2001-04-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with gastric cancer and methods for diagnosing and treating gastric cancer
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6440663B1 (en) 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
AU5632500A (en) 1999-06-30 2001-01-31 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
AU4903101A (en) 1999-11-30 2001-07-09 Cornell Research Foundation Inc. Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2001053349A2 (en) * 2000-01-21 2001-07-26 Ludwig Institute For Cancer Research Small cell lung cancer associated antigens and uses therefor
US6448073B1 (en) 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
ATE474931T1 (de) * 2000-04-28 2010-08-15 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
PT1319064E (pt) * 2000-07-27 2008-02-29 Novartis Vaccines & Diagnostic Polipéptidos de gsk3
US20040086852A1 (en) * 2000-12-01 2004-05-06 Toshiro Ono Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
EP2314712B1 (de) * 2001-11-07 2014-01-08 Mannkind Corporation Für Epitope von Antigenen kodierende Expressionsvektoren sowie Verfahren zu deren Konzeption
ATE519115T1 (de) 2002-06-13 2011-08-15 Merck Patent Gmbh Verfahren für die identifizierung von allo- antigenen und ihre verwendung für krebstherapie und transplantation
US8177823B2 (en) * 2005-06-30 2012-05-15 Depuy Spine Sarl Orthopedic clamping hook assembly
US8672732B2 (en) * 2006-01-19 2014-03-18 Schneider Electric It Corporation Cooling system and method
EP2046344A2 (de) * 2006-07-14 2009-04-15 MannKind Corporation Verfahren zur auslösung, verstärkung und aufrechterhaltung von immunreaktionen gegen eingeschränkte klasse-i-mhc-epitope für prophylaktische oder therapeutische zwecke
MX2009008620A (es) 2007-02-15 2009-10-22 Mannkind Corp Un metodo para mejorar la respuesta de celulas t.
JP2010528591A (ja) * 2007-05-23 2010-08-26 マンカインド コーポレイション マルチシストロン性ベクター及びそれらの設計方法
WO2009054471A1 (ja) 2007-10-25 2009-04-30 Toray Industries, Inc. 免疫誘導剤
CA2730201C (en) 2008-07-10 2019-02-05 Toray Industries, Inc. Anti-cd179b antibody
MX348464B (es) 2008-08-05 2017-06-14 Toray Industries Agente inductor de inmunidad.
CN106039307A (zh) 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
KR101606779B1 (ko) * 2008-08-05 2016-03-28 도레이 카부시키가이샤 암의 검출 방법
US8748103B2 (en) * 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
EP2364368B1 (de) 2008-11-07 2014-01-15 Sequenta, Inc. Verfahren zur überwachung von krankheitszuständen mittels sequenzanalyse
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
ES2726702T3 (es) 2009-01-15 2019-10-08 Adaptive Biotechnologies Corp Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
MX2011009597A (es) 2009-03-17 2012-05-29 Glaxosmithkline Biolog Sa Deteccion mejorada de la expresion del gen.
RU2539032C2 (ru) 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета
CA2778707A1 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
CN102821788B (zh) 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
KR101758117B1 (ko) 2010-02-04 2017-07-14 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
KR101843807B1 (ko) 2010-02-04 2018-03-30 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
CN102822335B (zh) 2010-02-04 2015-09-30 东丽株式会社 癌的治疗和/或预防用药物组合物
HUE030102T2 (en) 2010-02-04 2017-04-28 Toray Industries A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
AU2012256756B2 (en) * 2011-05-19 2017-06-08 Toray Industries, Inc. Immunity induction agent
CA2836568C (en) 2011-05-19 2020-07-21 Toray Industries, Inc. Immunity induction agent
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
JP6065592B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び/又は予防用医薬組成物
WO2013018894A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び/又は予防用医薬組成物
MX351414B (es) 2011-08-04 2017-10-13 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
EP2740793B1 (de) 2011-08-04 2017-11-29 Toray Industries, Inc. Arzneimittelzusammensetzung zur krebsbehandlung und/oder vorbeugung
KR101980554B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012325791B2 (en) 2011-10-21 2018-04-05 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2858070C (en) 2011-12-09 2018-07-10 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
MX363136B (es) 2012-02-21 2019-03-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
EP2818482B1 (de) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmazeutische zusammensetzung zur behandlung und von krebs
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
ES2662128T3 (es) 2012-03-05 2018-04-05 Adaptive Biotechnologies Corporation Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes
HUE036424T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
HUE029357T2 (en) 2012-05-08 2017-02-28 Adaptive Biotechnologies Corp Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
US20160002731A1 (en) 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
CN105452294B (zh) 2013-08-09 2019-08-02 东丽株式会社 癌的治疗和/或预防用药物组合物
ES2741740T3 (es) 2014-03-05 2020-02-12 Adaptive Biotechnologies Corp Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (de) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen
US10392663B2 (en) 2014-10-29 2019-08-27 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
PT3290051T (pt) 2015-04-30 2020-01-07 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção de cancro
HUE052947T2 (hu) 2015-04-30 2021-05-28 Toray Industries Immunitásindukáló ágens
CN107604092A (zh) * 2017-11-01 2018-01-19 中国医学科学院药用植物研究所 一种朝鲜淫羊藿与粗毛淫羊藿的分子鉴定方法
CN107619876A (zh) * 2017-11-01 2018-01-23 中国医学科学院药用植物研究所 一种箭叶淫羊藿与天平山淫羊藿的分子鉴定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) * 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5274087A (en) * 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
IE911129A1 (en) * 1990-04-04 1991-10-09 Chiron Corp Hepatitis c virus protease
AT401180B (de) * 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5585464A (en) * 1993-02-19 1996-12-17 Theratech, Inc. Recombinant antigen for diagnosing rheumatoid arthritis
NZ263050A (en) * 1993-03-05 1997-11-24 Cytel Corp Compositions of immunogenic peptides with hla-a2.1 binding motifs
FR2705362B1 (fr) * 1993-05-18 1995-08-04 Agronomique Inst Nat Rech Clônage et expression du gêne de l'enzyme malolactique de Lactococcus lactis.
WO1995014772A1 (fr) * 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma

Also Published As

Publication number Publication date
AU6165296A (en) 1996-12-30
ATE222116T1 (de) 2002-08-15
US5798264A (en) 1998-08-25
DE69627056D1 (de) 2003-04-30
CA2223566A1 (en) 1996-12-19
EP0831879B1 (de) 2002-08-14
DE69623014T2 (de) 2003-05-08
DK0831879T3 (da) 2002-12-16
EP0831879A4 (de) 2000-01-26
JP2002502354A (ja) 2002-01-22
AU704109B2 (en) 1999-04-15
ES2180782T3 (es) 2003-02-16
EP0831879A1 (de) 1998-04-01
CA2223566C (en) 2002-09-03
PT831879E (pt) 2002-12-31
US5698396A (en) 1997-12-16
CN1136914C (zh) 2004-02-04
WO1996040209A1 (en) 1996-12-19
DE69623014D1 (de) 2002-09-19
DE69627056T2 (de) 2004-01-29
CN1190894A (zh) 1998-08-19

Similar Documents

Publication Publication Date Title
ATE235248T1 (de) Verfahren zur identifizierung und isolierung von einem molekül
DE59804008D1 (de) Verfahren zur identifikation von nucleinsäuren durch matrix-assistierte laser desorptions/ionisations massenspektrometrie
DE69632466D1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
ATE397092T1 (de) Methode zur direkten sequenzierung von nukleinsäuren
WO1998022589A3 (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
ATE503843T1 (de) Gesamt-chromosom analyse von protein-dns wechselwirkungen
DE60110769D1 (de) Verfahren und vorrichtung zur analyse von geladenen molekülen durch isoelektrische fokussierung einer lösung
ATE332505T1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
DE69422339D1 (de) Verfahren zur Nachweis von Marijuana in einer Haar Probe
DE69618614D1 (de) NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG
DE59408917D1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
NO924912D0 (no) Fremgangsmaate ved paavisning av analyttvarianter, samt sett for utfoerelse av fremgangsmaaten
Swerdlow et al. Affinity of HMG17 for a mononucleosome is not influenced by the presence of ubiquitin-H2A semihistone but strongly depends on DNA fragment size
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
ATE509946T1 (de) Fluoreszenzproteine und chromoproteine aus nicht- aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
DE69731103D1 (de) Verfahren zur proteinextraktion
DE69927691D1 (de) Verfahren zur eiweissanalyse
Egyházi et al. Phosphorylation of some chromosomal nonhistone proteins in active genes is blocked by the transcription inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB).
ATE405592T1 (de) Verfahren zur bildung eines protein- mikroarraysystems
WO2001016170A3 (en) Card proteins involved in cell death regulation
EA199800843A1 (ru) Компьютерный способ создания химических структур, имеющих общие функциональные характеристики
WO1998024902A8 (en) Adaptor protein frs2 and related products and methods
ATE30357T1 (de) Verfahren zur halogenbestimmung in organischen proben.
WO1998002557A3 (en) MAMMALIAN TNF-α CONVERTASES

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties